Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV-infected males and non-pregnant/non-lactating females~* Treatment-naïve or treatment-experienced individuals~* Compensated cirrhosis at Screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).